AT-7519 is under clinical development by Astex Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AT-7519’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Smarter leaders trust GlobalData
AT-7519 overview
AT-7519 is under development for the treatment of relapsed mantle cell lymphoma, advanced or metastatic solid tumors and solid tumors that cannot be removed by surgery. It is administered through intravenous route. It is a small molecule targeted inhibitor of CDK1, CDK2 and CDK9. The drug is developed based on Pyramid technology. It was also under development for the treatment of colon cancer, relapsed or refractory multiple myeloma and refractory non-Hodgkin's lymphoma, relapsed or refractory chronic lymphocytic leukemia (CLL).
Astex Pharmaceuticals overview
Astex Pharmaceuticals, a subsidiary of Otsuka Holdings Co Ltd, is a drug discovery and development company with a focus on cancer and central nervous system (CNS) diseases. The company’s proprietary fragment-based drug discovery platform, Pyramid delivers high-quality and customized drug leads across a variety of therapeutic targets and disease areas. Its pipeline product and programs include DNMT inhibitor, Oral DNMT inhibitor, dual IAP antagonist, oral murine double minute 2 (MDM2) antagonist and extracellular signal-related protein kinases inhibitor. Astex Pharmaceuticals is also advancing several of its compounds into clinical trials in collaboration with Novartis, AstraZeneca, GSK, and Janssen. The company operates as a subsidiary of Otsuka Pharmaceutical Co Ltd. Astex Pharmaceuticals is headquartered in Pleasanton, California, the US.
For a complete picture of AT-7519’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
